KEYNOTE-028 was an international, multicenter, open-label, nonrandomized, single-arm phase Ib trial that was designed to assess the safety of pembrolizumab and to explore whether pembrolizumab showed antitumor activity in 20 different cohorts of patients with advanced solid tumors considered to have significant unmet medical need.What is the ketnote-028 study design?
The KETNOTE-028 study was designed as a multicohort, single-arm, non-randomized study evaluating 20 PD-L1–positive advanced solid tumor types. Because of the multicohort design, the sample size for any given tumor type, including CRC, was small (approximately 22 patients per tumor type), and there were no active comparator groups.Is pd-l1-positive endometrial cancer advanced?
The results from the advanced endometrial cancer cohort are reported. Patients and Methods Female patients with locally advanced or metastatic PD-L1-positive endometrial cancer who had experienced progression after standard therapy were eligible.What is dMMR in endometrial cancer?
MSI-H/dMMR Endometrial Cancer. Endometrial cancer (EC) is the most common gynecologic cancer, with a 1% increase in incidence and mortality in the last year. Approximately 2%–5% of EC cases have a defective germline DNA mismatch repair system (dMMR) attributed to Lynch syndrome.